文献速递细菌感染、耐药与抗菌药物

替考拉宁抗MRSA的药效动力学研究

Pharmacodynamics of teicoplanin against MRSA.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

研究通过中空纤维感染模型和中性粒细胞减少小鼠大腿感染模型,结合群体药动学建模与蒙特卡洛模拟,确定替考拉宁抗MRSA的体内AUC/MIC疗效靶值及抑制耐药靶值,并评估标准剂量在欧洲药敏试验委员会野生型敏感范围内的靶值 attainment 概率。

要点

  • 替考拉宁呈浓度依赖性杀菌活性,体内疗效靶值为总AUC/MIC 610.4。
  • 抑制耐药出现需总AUC/MIC约1500。
  • 标准剂量仅当MIC≤0.125 mg/L(成人)或≤0.064 mg/L(儿童)时可达杀菌靶值。

核心结论

  • 替考拉宁对MRSA的疗效和耐药抑制与总AUC/MIC相关,体内杀菌靶值为610.4,抑制耐药靶值约为1500。

研究设计与样本

  • 采用中空纤维感染模型和中性粒细胞减少小鼠大腿感染模型,用Pmetrics非参数群体建模,并结合成人及儿童群体PK模型进行蒙特卡洛模拟。

主要发现

  • 替考拉宁在体外和体内模型中均呈浓度依赖性活性。
  • 对MIC为0.5 mg/L的MRSA菌株,达到2 log10细胞杀灭需总AUC/MIC 610.4(总AUC 305.2 mg·h/L)。
  • 抑制耐药出现需总AUC/MIC约1500(总AUC约750 mg·h/L)。
  • 标准方案下,成人MIC≤0.125 mg/L、儿童MIC≤0.064 mg/L时PTA方可达到体内杀菌靶值。

关键数值与推荐

  • 体内疗效靶值:总AUC/MIC 610.4(总AUC 305.2 mg·h/L),对应MIC 0.5 mg/L的MRSA菌株。
  • 抑制耐药靶值:总AUC/MIC约1500(总AUC约750 mg·h/L)。
  • 标准剂量达标条件:成人MIC≤0.125 mg/L,儿童MIC≤0.064 mg/L。

临床怎么用

  • 临床可参考AUC/MIC靶值评估替考拉宁对MRSA的疗效和耐药抑制,尤其关注MIC是否在标准剂量可达标范围内。

局限性

  • 需在更多感染模型和患者中进一步验证该PK/PD指数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The overall study aim was to identify the relevant preclinical teicoplanin pharmacokinetic (PK)/pharmacodynamic (PD) indices to predict efficacy and suppression of resistance in MRSA infection. METHODS: A hollow-fibre infection model and a neutropenic murine thigh infection model were developed. The PK/PD data generated were modelled using a non-parametric population modelling approach with Pmetrics. The posterior Bayesian estimates derived were used to study the exposure-effect relationships. Monte Carlo simulations from previously developed population PK models in adults and children were conducted to explore the probability of target attainment (PTA) for teicoplanin dosage regimens against the current EUCAST WT susceptibility range. RESULTS: There was a concentration-dependent activity of teicoplanin in both the in vitro and in vivo models. A total in vivo AUC/MIC of 610.4 (total AUC of 305.2 mg·h/L) for an MRSA strain with an MIC of 0.5 mg/L was needed for efficacy (2 log10 cell kill) against a total bacterial population. A total AUC/MIC ratio of ∼1500 (total AUC of ∼750 mg·h/L) was needed to suppress the emergence of resistance. The PTA analyses showed that adult and paediatric patients receiving a standard regimen were only successfully treated for the in vivo bactericidal target if the MIC was ≤0.125 mg/L in adults and ≤0.064 mg/L in children. CONCLUSIONS: This study improves our understanding of teicoplanin PD against MRSA and defines an in vivo AUC/MIC target for efficacy and suppression of resistance. Additional studies are needed to further corroborate the PK/PD index in a variety of infection models and in patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ramos-Martín V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother. 2017. PMID: 28962026. doi:10.1093/jac/dkx289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。